Weekly Recap | Caris Life Sciences -2.91%, most brokers rate it buy

The Week

Caris Life Sciences (CAI.US) closed the week at $24.34, down 2.91%, while the S&P 500 declined 0.8%. That puts the stock about 2.11 percentage points behind the benchmark. Trading was soft across the four sessions: it opened Tuesday at $25.03 and touched a weekly high of $25.68 before fading, then slid to a low of $23.20 on Thursday and steadied to finish Friday at $24.34. The week’s range was 9.91%, and average daily volume of roughly 3.05m shares ran about 20.8% below the 60-day median. There were no major catalysts, with price action largely tracking the broader market lower.

Analyst Ratings

Fourteen firms cover the stock: 9 rate it buy, 1 overweight, and 4 hold, with no underweight or sell ratings. The consensus rating is buy, with a consensus target of $27.54, about 13.1% above the current price. Individual targets range from $22.00 to $36.00, suggesting meaningful dispersion across analysts. Within the biotech industry, the stock ranks 78th out of 506 names by rating score.

The Week Ahead

Macro data dominates the coming week. On Tuesday 15 September, the New York Fed manufacturing index is due, with a prior reading of 20.6 and consensus at 14.75. Wednesday 16 September brings retail sales, retail sales ex-autos, and the NAHB housing market index, among other releases. No company earnings are scheduled. The new Caris Detect national ad featuring Kevin Costner, launched during the week, may also keep the brand in the conversation.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.